National Health (Originator Brand) Amendment Determination 2017 (No. 3) (PB 33 of 2017) (Cth)

PB 33 of 2017

National Health (Originator Brand) Amendment Determination 2017 (No. 3)

National Health Act 1953

I, KAREN BINNEKAMP, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated           28 April 2017

______________________________________

KAREN BINNEKAMP

Assistant Secretary (Acting)

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2017 (No. 3).

(2)     This Determination may also be cited as PB 33 of 2017.

1. Commencement

This Determination commences on 1 May 2017.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1 (after table item 233)

insert:

233A Tranexamic Acid Cyklokapron